

Zahinoor Ismail

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5042981/publications.pdf>

Version: 2024-02-01

187
papers

7,551
citations

71102

41
h-index

71685

76
g-index

208
all docs

208
docs citations

208
times ranked

7081
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitive profile of people with mild behavioral impairment in Brain Health Registry participants. <i>International Psychogeriatrics</i> , 2023, 35, 643-652.	1.0	25
2	Reliability and Validity of the Traditional Chinese Version of the Mild Behavioral Impairment Checklist Among Persons With Mild Cognitive Impairment: A Validation Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2023, 36, 26-38.	2.3	6
3	Validating the Mild Behavioral Impairment Checklist in a Cognitive Clinic: Comparisons With the Neuropsychiatric Inventory Questionnaire. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2023, 36, 107-120.	2.3	28
4	Mediators of cognitive impairment in cerebral amyloid angiopathy. <i>International Journal of Stroke</i> , 2023, 18, 78-84.	5.9	7
5	Efficacy of virtual interventions for reducing symptoms of depression in community-dwelling older adults: a systematic review. <i>International Psychogeriatrics</i> , 2023, 35, 131-141.	1.0	3
6	Network analysis of impulse dyscontrol in mild cognitive impairment and subjective cognitive decline. <i>International Psychogeriatrics</i> , 2022, 34, 553-562.	1.0	15
7	Plasma β -Amyloid in Mild Behavioural Impairment: Neuropsychiatric Symptoms on the Alzheimer's Disease Continuum. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 434-441.	2.3	44
8	Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 119-147.	1.2	28
9	Prevalence of mild behavioural impairment domains: a meta-analysis. <i>Psychogeriatrics</i> , 2022, 22, 84-98.	1.2	10
10	Psychosis in Alzheimer disease: mechanisms, genetics and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2022, 18, 131-144.	10.1	62
11	Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 2.	6.2	39
12	Informant-based tools for assessment and monitoring of cognition, behavior, and function in neurocognitive disorders: Systematic review and report from a CCCDTD5 Working Group. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	2
13	CCCDT5 recommendations on the deprescribing of cognitive enhancers in dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12099.	3.7	3
14	Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study. <i>Alzheimer's and Dementia</i> , 2022, 18, 2199-2208.	0.8	28
15	The Relationship Between Hearing and Mild Behavioral Impairment and the Influence of Sex: A Study of Older Adults Without Dementia from the COMPASS-ND Study. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 57-66.	2.2	11
16	The Rationale and Design of Behavioral Interventions for Management of Agitation in Dementia in a Multi-Site Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 827-840.	2.6	1
17	Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy. <i>Neurology</i> , 2022, 98, .	1.1	14
18	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	5.4	30

#	ARTICLE	IF	CITATIONS
19	Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1721-1734.	2.6	3
20	Detecting depression in persons living with mild cognitive impairment: a systematic review. <i>International Psychogeriatrics</i> , 2022, 34, 453-465.	1.0	5
21	Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms. <i>Neurology</i> , 2022, 98, .	1.1	42
22	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 48.	6.2	42
23	Dual-task gait and mild behavioral impairment: The interface between non-cognitive dementia markers. <i>Experimental Gerontology</i> , 2022, 162, 111743.	2.8	10
24	A pragmatic dementia risk score for patients with mild cognitive impairment in a memory clinic population: Development and validation of a dementia risk score using routinely collected data. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12301.	3.7	5
25	Delusional Severity Is Associated with Abnormal Texture in FLAIR MRI. <i>Brain Sciences</i> , 2022, 12, 600.	2.3	0
26	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 345-355.	2.6	19
27	Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1203-1228.	2.6	7
28	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	4.8	78
29	Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12164.	2.4	32
30	Patterns of brain activity during a set-shifting task linked to mild behavioral impairment in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2021, 30, 102590.	2.7	10
31	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	8.0	17
32	Mortality Risk Models for Persons with Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 103-111.	2.6	12
33	Mild Behavioral Impairment and Subjective Cognitive Decline Predict Cognitive and Functional Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 459-469.	2.6	77
34	Neural correlates of the impulse dyscontrol domain of mild behavioral impairment. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1398-1406.	2.7	47
35	Diagnostic criteria for apathy in neurocognitive disorders. <i>Alzheimer's and Dementia</i> , 2021, 17, 1892-1904.	0.8	71
36	Mild Behavioral Impairment Is Associated With Atrophy of Entorhinal Cortex and Hippocampus in a Memory Clinic Cohort. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 643271.	3.4	63

#	ARTICLE	IF	CITATIONS
37	Factors Associated with Hyponatremia in Patients Newly Prescribed Citalopram: A Retrospective Observational Study. <i>Drugs - Real World Outcomes</i> , 2021, 8, 555-563.	1.6	4
38	The Association Between Diabetes Mellitus and Mild Behavioral Impairment Among Mild Cognitive Impairment: Findings from Singapore. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 411-420.	2.6	6
39	Reliability and Validity of the Chinese Version of Mild Behavioral Impairment Checklist in Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1141-1149.	2.6	15
40	Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria. <i>Alzheimer's and Dementia</i> , 2021, 17, 1687-1697.	0.8	8
41	D-cycloserine normalizes long-term motor plasticity after transcranial magnetic intermittent theta-burst stimulation in major depressive disorder. <i>Clinical Neurophysiology</i> , 2021, 132, 1770-1776.	1.5	10
42	Neural Correlates of Mild Behavioral Impairment: A Functional Brain Connectivity Study Using Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1221-1231.	2.6	14
43	White matter hyperintensities and mild behavioral impairment: Findings from the MEMENTO cohort study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100028.	0.9	7
44	Non-pharmacologic interventions to treat apathy in Parkinson's disease: A realist review. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 4, 100096.	0.9	6
45	Understanding the impact of the COVID-19 pandemic on well-being and virtual care for people living with dementia and care partners living in the community. <i>Dementia</i> , 2021, 20, 2007-2023.	2.0	56
46	Cerebral Amyloid Angiopathy Is Associated With Emotional Dysregulation, Impulse Dyscontrol, and Apathy. <i>Journal of the American Heart Association</i> , 2021, 10, e022089.	3.7	9
47	Mild behavioral impairment is associated with amyloid, tau and neurodegeneration in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
48	Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 128.	1.9	8
49	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020, 32, 705-717.	1.0	57
50	The impact of traumatic brain injury on cognitive and neuropsychiatric symptoms of Parkinson's disease. <i>International Review of Psychiatry</i> , 2020, 32, 46-60.	2.8	6
51	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. <i>Neuropsychopharmacology</i> , 2020, 45, 283-291.	5.4	37
52	Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2020, 58, 101004.	10.9	17
53	Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale "Depression subscale scores: An individual participant data meta-analysis of 73 primary studies. <i>Journal of Psychosomatic Research</i> , 2020, 129, 109892.	2.6	33
54	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	2.6	39

#	ARTICLE	IF	CITATIONS
55	M191. EFFECT OF BREXPIRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES. <i>Schizophrenia Bulletin</i> , 2020, 46, S208-S209.	4.3	1
56	Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 1256-1269.	1.2	40
57	Depression prevalence using the HADS-D compared to SCID major depression classification: An individual participant data meta-analysis. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110256.	2.6	19
58	Remote cognitive and behavioral assessment: Report of the Alzheimer Society of Canada Task Force on dementia care best practices for COVID-19. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12111.	2.4	63
59	CCCDT5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12057.	3.7	9
60	Mild behavioral impairment is related to frailty in non-dementia older adults: a cross-sectional study. <i>BMC Geriatrics</i> , 2020, 20, 510.	2.7	20
61	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1182-1195.	0.8	119
62	Agitation and impulsivity in mid and late life as possible risk markers for incident dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12016.	3.7	25
63	CCCDT5 recommendations on early non cognitive markers of dementia: A Canadian consensus. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12068.	3.7	29
64	The pathway to secondary prevention of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12069.	3.7	5
65	Diagnosis, treatment and management of apathy in Parkinson's disease: a scoping review. <i>BMJ Open</i> , 2020, 10, e037632.	1.9	37
66	Mild Behaviour Impairment Checklist (MBI-C): Is there a difference in ratings between patient and close informant?. <i>Alzheimer's and Dementia</i> , 2020, 16, e039239.	0.8	1
67	Relationship between genetic risk for Alzheimer's, cognition and neuropsychiatric symptoms: A case study of DNA sampling and analysis through digital platform cohort studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e040237.	0.8	0
68	Gait impairments on single and dual tasks in cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e041325.	0.8	1
69	Neuropsychiatric symptoms in subjective cognitive complaints (SCC) and mild cognitive impairment (MCI): Detecting changes over time with the Mild Behavioral Impairment Checklist (MBI-C). <i>Alzheimer's and Dementia</i> , 2020, 16, e041963.	0.8	4
70	Mild behavioral impairment is associated with atrophy in Alzheimer's disease-related regions in non-demented older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e044819.	0.8	3
71	Mild behavioral impairment associates with Alzheimer's disease biomarkers and greater risk of incident dementia in patients with MCI. <i>Alzheimer's and Dementia</i> , 2020, 16, e044905.	0.8	0
72	Characterising mild behavioural impairment in Asian mild cognitive impairment and cognitively normal individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e045059.	0.8	2

#	ARTICLE	IF	CITATIONS
73	ApoE ϵ 4 status in pre-dementia risk states, mild behavioural impairment and subjective cognitive decline, and the risk of incident cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e046615.	0.8	7
74	Cognitive profile of mild behavioral impairment (MBI) in brain health registry participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e047673.	0.8	9
75	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12098.	2.4	13
76	Trial of remote ischaemic preconditioning in vascular cognitive impairment (TRIC-VCI): protocol. <i>BMJ Open</i> , 2020, 10, e040466.	1.9	7
77	Common and unique connectivity at the interface of motor, neuropsychiatric, and cognitive symptoms in Parkinson's disease: A commonality analysis. <i>Human Brain Mapping</i> , 2020, 41, 3749-3764.	3.6	10
78	Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1017-1027.	2.6	68
79	Partnering With Family Members to Detect Delirium in Critically Ill Patients*. <i>Critical Care Medicine</i> , 2020, 48, 954-961.	0.9	21
80	Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies. <i>Journal of Psychopharmacology</i> , 2020, 34, 829-838.	4.0	5
81	Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 192-199.	0.8	102
82	Aberrant limbic brain structures in young individuals at risk for mental illness. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 294-302.	1.8	14
83	Mild behavioral impairment in Parkinson's disease is associated with altered corticostriatal connectivity. <i>NeuroImage: Clinical</i> , 2020, 26, 102252.	2.7	25
84	Using Machine Learning to Predict Dementia from Neuropsychiatric Symptom and Neuroimaging Data. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 277-288.	2.6	74
85	Building machine learning models without sharing patient data: A simulation-based analysis of distributed learning by ensembling. <i>Journal of Biomedical Informatics</i> , 2020, 106, 103424.	4.3	24
86	Association Between BDNF Val66Met Polymorphism and Mild Behavioral Impairment in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 587992.	2.4	13
87	Alzheimer Disease, Biomarkers, and Clinical Symptoms—Quo Vadis?. <i>JAMA Neurology</i> , 2020, 77, 393.	9.0	7
88	Pandemic Dementia Scarce Resource Allocation. <i>Canadian Geriatrics Journal</i> , 2020, 23, 260-262.	1.2	9
89	Evaluating the Real-World Representativeness of Participants with Mild Cognitive Impairment in Canadian Research Protocols: a Comparison of the Characteristics of a Memory Clinic Patients and Research Samples. <i>Canadian Geriatrics Journal</i> , 2020, 23, 297-328.	1.2	1
90	Evaluating the real-world representativeness of participants with mild cognitive impairment in Canadian research protocols: a comparison of the characteristics of a memory clinic patients and research samples. <i>Canadian Geriatrics Journal</i> , 2020, 23, 297-328.	1.2	3

#	ARTICLE	IF	CITATIONS
91	Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. <i>International Psychogeriatrics</i> , 2019, 31, 231-239.	1.0	80
92	Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease. <i>Neurology</i> , 2019, 93, e766-e777.	1.1	45
93	Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease/Mild Cognitive Impairment: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 477-501.	2.6	25
94	Detecting Apathy in Individuals with Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2019, 9, 653-664.	2.8	4
95	Escitalopram for agitation in Alzheimer's disease (SCITAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. <i>Alzheimer's and Dementia</i> , 2019, 15, 1427-1436.	0.8	28
96	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 823-834.	1.2	144
97	Prevalence of Mild Behavioral Impairment and Risk of Dementia in a Psychiatric Outpatient Clinic. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 505-513.	2.6	78
98	Clinically Relevant Anti-Neuronal Cell Surface Antibodies in Schizophrenia Spectrum Disorders. <i>Neuropsychobiology</i> , 2019, 78, 70-78.	1.9	11
99	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. <i>NeuroImage</i> , 2019, 197, 589-597.	4.2	24
100	Feasibility and acceptability of family administration of delirium detection tools in the intensive care unit: a patient-oriented pilot study. <i>CMAJ Open</i> , 2019, 7, E294-E299.	2.4	34
101	P4566: SUBJECTIVE COGNITIVE DECLINE (SCD) AND MILD BEHAVIORAL IMPAIRMENT (MBI) TOGETHER PREDICT MILD COGNITIVE IMPAIRMENT AT 3 YEARS BETTER THAN EITHER SYNDROME ALONE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1535.	0.8	2
102	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019, 10, 1398.	3.5	17
103	Improved Automatic Morphology-Based Classification of Parkinson's Disease and Progressive Supranuclear Palsy. <i>Clinical Neuroradiology</i> , 2019, 29, 605-614.	1.9	5
104	Gray Matter Changes Associated With the Development of Delusions in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 490-498.	1.2	21
105	Comment on "Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment". <i>Journal of the American Geriatrics Society</i> , 2019, 67, 190-191.	2.6	8
106	Effect of Hearing Ability and Mild Behavioural Impairment on MoCA and Memory Index Scores. <i>Canadian Geriatrics Journal</i> , 2019, 22, 165-170.	1.2	9
107	Mild Behavioral Impairment: presentation of the diagnostic criteria and the Italian version of the MBI-Checklist. <i>Rivista Di Psichiatria</i> , 2019, 54, 59-66.	0.6	3
108	Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. <i>International Psychogeriatrics</i> , 2018, 30, 167-169.	1.0	13

#	ARTICLE	IF	CITATIONS
109	Dementia clinical trial implications of mild behavioral impairment. <i>International Psychogeriatrics</i> , 2018, 30, 171-175.	1.0	55
110	Case series of mild behavioral impairment: toward an understanding of the early stages of neurodegenerative diseases affecting behavior and cognition. <i>International Psychogeriatrics</i> , 2018, 30, 273-280.	1.0	29
111	Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. <i>International Psychogeriatrics</i> , 2018, 30, 221-232.	1.0	96
112	Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria. <i>International Psychogeriatrics</i> , 2018, 30, 185-196.	1.0	145
113	Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. <i>International Psychogeriatrics</i> , 2018, 30, 233-244.	1.0	111
114	P1â€³52: WHAT CAN THE MILD BEHAVIORAL IMPAIRMENT CHECKLIST (MBIâ€³) TELL US ABOUT COGNITION AND BEHAVIOR IN PARKINSON'S DISEASE?. <i>Alzheimer's and Dementia</i> , 2018, 14, P429.	0.8	1
115	P3â€³54: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATIONâ€³BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1335.	0.8	2
116	P1â€³523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBIâ€³) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P532.	0.8	0
117	P2â€³293: IS DEPRESSION REALLY DEPRESSION IN A MEMORY CLINIC? PREVALENCE, SCREENING AND DIAGNOSTIC ISSUES IN NEUROCOGNITIVE DISORDERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P794.	0.8	0
118	F4â€³03â€³02: INCREASED ATROPHY IN THE DEFAULT MODE NETWORK IS ASSOCIATED WITH DEVELOPMENT OF DELUSIONS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1386.	0.8	0
119	P2â€³292: MILD BEHAVIORAL IMPAIRMENT (MBI) IN MCI, SCD, AND NORMAL ELDERLY: A PILOT STUDY FOR VALIDATION OF THE MILD BEHAVIORAL IMPAIRMENT CHECKLIST (MBIâ€³). <i>Alzheimer's and Dementia</i> , 2018, 14, P793.	0.8	7
120	P4â€³110: MILD BEHAVIORAL IMPAIRMENT CHECKLIST (MBIâ€³): A PRELIMINARY VALIDATION STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1481.	0.8	8
121	Meta-Analysis of the Prevalence of Major Depressive Disorder Among Older Adults With Dementia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	46
122	Diagnostic accuracy of the Geriatric Depression Scale-30, Geriatric Depression Scale-15, Geriatric Depression Scale-5 and Geriatric Depression Scale-4 for detecting major depression: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2018, 8, e026598.	1.9	24
123	P3â€³336: SUBJECTIVE COGNITIVE DECLINE (SCD) AND MILD BEHAVIORAL IMPAIRMENT (MBI): THE INTERSECTION OF TWO EARLY INDICATORS OF AD PATHOPHYSIOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1210.	0.8	0
124	Association of Alzheimer's genetic loci with mild behavioral impairment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 727-735.	1.7	49
125	Assessing Mild Behavioral Impairment with the Mild Behavioral Impairment-Checklist in People with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 83-95.	2.6	113
126	Dispensary cannabidiol marijuana and first-episode mania. <i>Journal of Psychiatry and Neuroscience</i> , 2018, 43, 215-216.	2.4	0

#	ARTICLE	IF	CITATIONS
127	Apathy associated with neurocognitive disorders: Recent progress and future directions. <i>Alzheimer's and Dementia</i> , 2017, 13, 84-100.	0.8	167
128	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 929-938.	2.6	306
129	Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	39
130	Prevalence of Depression in Patients With Mild Cognitive Impairment. <i>JAMA Psychiatry</i> , 2017, 74, 58.	11.0	342
131	Neuropsychiatric Symptoms and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 141-153.	2.6	37
132	A practical approach to detection and treatment of depression in Parkinson disease and dementia. <i>Neurology: Clinical Practice</i> , 2017, 7, 128-140.	1.6	16
133	Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 347-350.	1.4	8
134	Cognitive and Neuropsychiatric Screening Tests in Older Adults. <i>Mental Health and Illness Worldwide</i> , 2017, , 343-368.	0.1	9
135	Physical Health and Drug Safety in Individuals with Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 673-683.	1.9	22
136	Canadian Guidelines for the Assessment and Diagnosis of Patients with Schizophrenia Spectrum and Other Psychotic Disorders. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 594-603.	1.9	28
137	Determining the impact of psychosis on rates of false positive and false negative diagnosis in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 385-392.	3.7	21
138	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 440-449.	3.7	240
139	[P1â€“296]: ASSESSING MILD BEHAVIORAL IMPAIRMENT IN PEOPLE WITH SUBJECTIVE COGNITIVE COMPLAINTS (SCCS) WITH THE MILD BEHAVIORAL IMPAIRMENT CHECKLIST (MBIâ€“C): A PILOT STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P364.	0.8	3
140	[P3â€“012]: OUTCOMES IN VASCULAR DEMENTIA TRIAL PATIENTS: A METAâ€“ANALYSIS OF PLACEBO DATA FROM PRIOR RANDOMIZED CONTROLLED TRIALS. <i>Alzheimer's and Dementia</i> , 2017, 13, P933.	0.8	0
141	[P1â€“140]: ALZHEIMER'S GENETIC RISK SCORE LINKED TO MILD BEHAVIORAL IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P296.	0.8	1
142	[P2â€“274]: MILD BEHAVIORAL IMPAIRMENT: WHAT ARE THE RISK FACTORS?. <i>Alzheimer's and Dementia</i> , 2017, 13, P719.	0.8	0
143	Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 283-295.	2.6	44
144	P2â€“027: Systematic Review of RCTS of Interventions for Vascular Cognitive Impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, P619.	0.8	0

#	ARTICLE	IF	CITATIONS
145	O1-05-05: Detection of Early Alzheimer's Disease From Blood Using Novel Microspectroscopy. , 2016, 12, P184-P185.		0
146	Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. <i>BMJ Open</i> , 2016, 6, e011913.	1.9	22
147	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 588-603.	1.9	165
148	Amyloid deposition in semantic dementia: a positron emission tomography study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1064-1074.	2.7	9
149	P2-176: Prevalence of Mild Behavioral Impairment (MBI) in a Memory Clinic Population and the Impact on Caregiver Burden. <i>Alzheimer's and Dementia</i> , 2016, 12, P683.	0.8	0
150	O1-13-03: The Mild Behavioral Impairment Checklist (MBI-C): a New Rating Scale for Neuropsychiatric Symptoms as Early Manifestations of Neurodegenerative Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P209.	0.8	0
151	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , 2016, 16, 105.	2.6	114
152	Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment. <i>Stroke</i> , 2016, 47, 2010-2016.	2.0	90
153	Gray matter atrophy in patients with mild cognitive impairment/Alzheimer's disease over the course of developing delusions. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 76-82.	2.7	31
154	Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 195-202.	0.8	493
155	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015, 27, 2059-2067.	1.0	22
156	Associations of medical comorbidity, psychosis, pain, and capacity with psychiatric hospital length of stay in geriatric inpatients with and without dementia. <i>International Psychogeriatrics</i> , 2015, 27, 313-321.	1.0	14
157	Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1127-1133.	1.2	22
158	Treatment-resistant depression in later life. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, E34-E35.	2.4	1
159	Grey Matter Atrophy in Mild Cognitive Impairment / Early Alzheimer Disease Associated with Delusions: A Voxel-Based Morphometry Study. <i>Current Alzheimer Research</i> , 2015, 12, 165-172.	1.4	29
160	Effect of Citalopram on Agitation in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 682.	7.4	447
161	Lacunar stroke, deep white matter disease and depression: a meta-analysis. <i>International Psychogeriatrics</i> , 2014, 26, 1101-1109.	1.0	13
162	Depression versus dementia: is this construct still relevant?. <i>Neurodegenerative Disease Management</i> , 2014, 4, 119-126.	2.2	30

#	ARTICLE	IF	CITATIONS
163	A Systematic Approach to Pharmacotherapy for Geriatric Major Depression. <i>Clinics in Geriatric Medicine</i> , 2014, 30, 517-534.	2.6	80
164	Cholinesterase-inhibitor Associated Mania: A Case Report and Literature Review. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 278-280.	0.5	12
165	Emerging Concepts in Geriatric Psychiatry: an Update on the Canadian Academy of Geriatric Psychiatry Annual Scientific Meeting. <i>Canadian Geriatrics Journal</i> , 2014, 17, 2-4.	1.2	1
166	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. <i>Psychopharmacology</i> , 2013, 228, 43-51.	3.1	15
167	Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: A Study Using the MATRICS Consensus Cognitive Battery. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 108-118.	1.2	68
168	A Comparison of the E-BEHAVE-AD, NBRS, and NPI in Quantifying Clinical Improvement in the Treatment of Agitation and Psychosis Associated With Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 78-87.	1.2	30
169	Canadian Academy of Geriatric Psychiatry Survey of Brief Cognitive Screening Instruments. <i>Canadian Geriatrics Journal</i> , 2013, 16, 54-60.	1.2	26
170	Delusions Increase Functional Impairment in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 393-399.	1.5	42
171	Development of a Core Set of Performance Measures for Evaluating Schizophrenia Treatment Services. <i>Psychiatric Services</i> , 2012, 63, 584-591.	2.0	20
172	Predicting Hospital Length of Stay for Geriatric Patients with Mood Disorders. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 696-703.	1.9	23
173	Impact of neuropsychiatric symptoms on caregiver burden in patients with Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 269-277.	2.2	31
174	Predicting Hospital Length of Stay for Geriatric Patients with Mood Disorders. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 627-634.	1.9	1
175	Citalopram for agitation in Alzheimer's disease: Design and methods. <i>Alzheimer's and Dementia</i> , 2012, 8, 121-130.	0.8	45
176	Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 53-60.	1.2	44
177	Neuroimaging of delusions in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 89-95.	1.8	56
178	Neurobiology of Delusions in Alzheimer's Disease. <i>Current Psychiatry Reports</i> , 2011, 13, 211-218.	4.5	51
179	Primary care physicians' attitudes towards cognitive screening: findings from a national postal survey. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 23-29.	2.7	40
180	Clozapine and Global Cognition in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 431-436.	1.4	35

#	ARTICLE	IF	CITATIONS
181	Brief cognitive screening instruments: an update. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 111-120.	2.7	357
182	Differentiating the Cognitive Profile of Schizophrenia from That of Alzheimer Disease and Depression in Late Life. <i>PLoS ONE</i> , 2010, 5, e10151.	2.5	29
183	Age at onset and cognition in schizophrenia: meta-analysis. <i>British Journal of Psychiatry</i> , 2009, 195, 286-293.	2.8	307
184	A SPECT Study of Sleep Disturbance and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 254-259.	1.5	19
185	The Perceptions and Habits of Alcohol Consumption and Smoking Among Canadian Medical Students. <i>Academic Psychiatry</i> , 2009, 33, 193-197.	0.9	16
186	Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 360-366.	2.0	57
187	A functional neuroimaging study of appetite loss in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2008, 271, 97-103.	0.6	40